# Gyre Therapeutics share price today (Gyre Therapeutics, Inc., GYRE)

> Gyre Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. GYRE · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/gyre

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.44 (−38.4% in a year)
- Revenue (Jun 2026): $29.1 M
- Profit (Jun 2026): −$11.7 M
- Operating margin: −47.6%
- ROE: 4%, FY25
- ROIC: −16.8%, against a 30.1% cost of capital: −46.9 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Gyre Therapeutics share price today? Gyre Therapeutics, Inc.'s share price was $4.44 at the close on 4 November 2026. That is 36.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $4 and $8, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 4 weeks running. Over the last 1 year the share price moved −41% while the S&P 500 moved +18%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Gyre Therapeutics pay? Gyre Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Gyre Therapeutics on? Gyre Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Gyre Therapeutics profitable? Gyre Therapeutics, Inc. posted a net loss of $11.7 M in the Jun 2026 quarter. Full-year FY25 profit was $5.0 M. That loss is 40.1% of the quarter's revenue. The same quarter a year earlier earned $3.5 M. 4 of the last 8 reported quarters were loss-making. For the full year, FY25 profit was $5.0 M (−58.4% on the year before). ## How much revenue does Gyre Therapeutics make, and is it growing? Gyre Therapeutics, Inc. reported $29.1 M of revenue in the Jun 2026 quarter. Over 4 years it has grown 99.6% a year on average. The last full year, FY25, came in at $117 M. The quarterly figures for FY25 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $117 M, +10.2% on the year before. ## How much of every $100 of sales does Gyre Therapeutics keep? Gyre Therapeutics, Inc.'s operating margin was −47.6% in the Jun 2026 quarter. Across 5 years it has been between −1,197.8% and 16.9%. The latest quarter is within that range. Why the margin moved: operating margin changed −60.5 percentage points on the year while gross margin changed −4.5 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Gyre Therapeutics' profit turning into cash? Over the last 3 years, 41% of Gyre Therapeutics, Inc.'s reported profit came in as cash from its operations, a gap worth watching. In FY25 it brought in $1.0 M of operating cash against $5.0 M of profit. After $1.2 M of spending on assets, free cash was −$180 K: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Gyre Therapeutics' cash go? Gyre Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $12.0 M on assets over the last 3 years. Averaged over those years that is 3.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $12.0 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Gyre Therapeutics' P/E ratio, and how does it compare with its own history? Gyre Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Gyre Therapeutics, Inc. at 4.0× its FY25 revenue of $117 M. The P/E comes back here once profit turns positive. Why the multiple is where it is: over the past year earnings per share moved −53.2% while the price moved −38.4%. The price did better than earnings, which pushed the multiple up within its own range. ## Is the Gyre Therapeutics business getting better or worse? Gyre Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Gyre Therapeutics earn on its capital? Gyre Therapeutics, Inc. earned a ROE of 4% in FY25. That is up from a low of −214% in FY21. Its return on capital used (ROIC) is 46.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 4.3% net margin and 0.70× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 4.3% net margin × 0.70× asset turnover × 1.17× leverage (assets divided by equity) ≈ 3.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −16.8% − 30.1% = −46.9 percentage points. The 30.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −16.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 9.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Gyre Therapeutics have too much debt? Gyre Therapeutics, Inc. has total debt of $3.4 M against shareholder equity of $165 M as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.06 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Gyre Therapeutics shareholding pattern? 5.4% of Gyre Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 9.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Gyre Therapeutics from balance-sheet trouble? For Gyre Therapeutics, Inc., the Z-score is 11.85. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 11.85 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Gyre Therapeutics rank in its industry? There is no score against its industry: Gyre Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Gyre Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Gyre Therapeutics in size? Gyre Therapeutics is the 146th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: REGENXBIO Inc., YD Bio and Arvinas, Inc. Just below it: MiMedx Group, Inc., Phathom Pharmaceuticals, Inc. and Oculis Holding AG. ### Biotechnology companies close in size

1. [REGENXBIO Inc.](https://www.sectoralpha.in/us/stocks/rgnx) $509 million
2. [YD Bio Limited](https://www.sectoralpha.in/us/stocks/ydes) $492 million
3. [Arvinas, Inc.](https://www.sectoralpha.in/us/stocks/arvn) $486 million
4. Gyre Therapeutics, Inc. $471 million
5. [MiMedx Group, Inc.](https://www.sectoralpha.in/us/stocks/mdxg) $467 million
6. [Phathom Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/phat) $451 million
7. [Oculis Holding AG](https://www.sectoralpha.in/us/stocks/ocs) $449 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Cerus Corporation](https://www.sectoralpha.in/us/stocks/cers) $472 million · Medical Devices
2. [Oculis Holding AG](https://www.sectoralpha.in/us/stocks/ocs) $471 million · Biotechnology
3. Gyre Therapeutics, Inc. $471 million
4. [Ovid Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/ovid) $469 million · Biotechnology
5. [Senseonics Holdings, Inc.](https://www.sectoralpha.in/us/stocks/sens) $468 million · Medical Devices

## What else do people ask about Gyre Therapeutics? ### What were Gyre Therapeutics's latest quarterly results? Gyre Therapeutics, Inc. reported revenue of $29.1 M and a net loss of $11.7 M for the Jun 2026 quarter. Earnings per share were −$0.12. The operating margin was −47.6% (as of 4 November 2026). ### What is Gyre Therapeutics's market cap? Gyre Therapeutics, Inc.'s market capitalisation is $471 M at a stock price of $4.44. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Gyre Therapeutics performing? Gyre Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 4 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Gyre Therapeutics's stock price go up? This page does not forecast Gyre Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $4.44. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Gyre Therapeutics in its business cycle? Gyre Therapeutics, Inc.'s FY25 operating margin was 9.9%, against a 5-year range of −1,197.8% to 16.9%: the middle of its own range, neither a peak nor a low. The latest quarter was −47.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Gyre Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Gyre Therapeutics a stock worth studying right now? What the numbers show: Gyre Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.